Cabaletta Bio CABA 深 沪
等待开盘 07-31 09:30:00 美东时间
1.56
-0.010
-0.64%
华盛通- 最 高1.65
- 今 开1.62
- 成交量 95.08万股
- 最 低 1.56
- 昨 收 1.57
- 总市值 1.40亿
- 52周最高 6.26
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 0.9857
- 委 比 70.43%
- 总股本 8994.31万
- 历史最高 26.35
- 量 比 1.01
- 振 幅 5.73%
- 历史最低 0.59
- 每 手 1
- 风险率 6.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
07-30 23:07
Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical stu...
07-18 00:23
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
06-30 20:36
砍完地产卖金融，雅戈尔拿什么再赚140亿？
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：源媒汇 作者 | 童画 过去十二个月，雅戈尔连续出售了...
06-27 16:36
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Analysts’ Top Healthcare Picks: Liquidia Technologies (LQDA), Cabaletta Bio (CABA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
06-12 15:20
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Cabaletta Bio slides on proposed securities offering
Cabaletta Bio (NASDAQ:CABA) shares fell 20% in premarket trade on Wednesday after the biotechnology company proposed a public offering of mixed securities. The company plans to offer shares of its com...
06-11 18:29
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio, a clinical-stage biotechnology company specializing in targeted cell therapies for autoimmune diseases, has initiated an underwritten public offering of its common stock and warrants, with underwriters having a 30-day option to purchase additional shares. The offering is subject to market conditions and is expected to close on June 12, 2025. Jefferies, TD Cowen, and Cantor are acting as joint book-running managers. The company aims...
06-11 10:15
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
Cabaletta Bio announced positive clinical data from its RESET trials evaluating rese-cel for treating myositis, lupus, and scleroderma. 7 of 8 myositis patients achieved meaningful responses off immunomodulators and steroids, with sustained outcomes. All 7 SLE patients achieved remission off therapy, and scleroderma patients showed significant skin improvement. Safety data showed minimal cytokine release syndrome (CRS) and ICANS events. The compa...
06-11 10:00
